1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Jinxin Fertility Group Ltd.

Jinxin Fertility Group Ltd.

2.18
HKD
-0.04
(-2.02%)
6.29BMarket Cap
Mar 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
0.28
0.39
0.75
0.59
0.74
0.95
1.04
1.05
0.97
- -
Basic EPS, GAAP
0.04
0.04
0.07
0.19
0.1
0.14
0.05
0.13
0.11
-0.36
- -
Free Cash Flow per Basic Share
0.04
0.01
0.14
0.08
-0.01
0.11
-0.17
0.19
0.14
0.12
- -
Dividend per Share
- -
0.03
0.05
0.15
0.06
- -
0.06
- -
0.06
- -
- -
Book Value per Share
0.03
0.39
1.83
3.09
3
3.41
3.43
3.71
3.84
3.46
3.46
Tangible Book Value per Share
0.03
0.03
-0.03
1.26
1.03
0.25
-0.42
0.14
0.21
0.2
0.2
Basic Weighted Avg Shares
2,381
2,381
2,381
2,199
2,400
2,478
2,496
2,676
2,681
2,742
2,694
Sales/Revenue/Turnover
346
663
922
1,648
1,426
1,839
2,364
2,789
2,812
2,649
- -
Operating Margin (%)
30.61
35.7
28.71
28.56
17.21
20.57
10.72
18.4
16.14
4.12
- -
Depreciation Expense
14
35
42
113
130
169
260
285
276
345
- -
Net Income, GAAP
88
99
167
410
252
340
121
345
283
-976
- -
Effective Tax Rate (%)
5.21
17.81
23.31
23.22
25.39
22.76
23.57
25.26
30.22
- -
- -
Profit Margin (%)
25.28
14.9
18.07
24.85
17.64
18.48
5.12
12.36
10.07
-36.85
- -
Working Capital
-448
331
59
2,990
2,097
1,472
-860
-347
-1,030
-192
-192
LT Debt
- -
- -
- -
153
354
1,990
2,447
1,729
1,274
2,173
2,173
Total Equity
101
1,362
4,500
7,642
7,462
8,753
8,735
10,187
10,354
9,199
9,199
Return on Invested Capital (%)
- -
25.53
6.66
5.73
2.37
3.09
1.4
2.79
2.46
- -
- -
Return on Capital (%)
- -
-0.13
4.13
6.58
3.22
3.66
1.51
3.14
2.59
- -
- -
Return on Common Equity (%)
- -
19.62
6.3
6.89
3.4
4.29
1.41
3.68
2.78
-10.05
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1,331
542
675
LT Borrowings
993
1,904
1,840
LT Finance Leases
281
363
333
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,676
2,681
2,641
Market Capitalization
6,764
7,487
5,649

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,090
1,190
1,249
Cash, Cash Equivalents & STI
571
720
906
Accounts Receivable, Net
234
199
138
Inventories
51
46
56
Total Current Liabilities
2,119
1,338
1,441
Payables & Accruals
- -
- -
- -
ST Debt
1,331
542
675
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.84%
-11.16%
Free Cash Flow
- -
-477.67%
-11.56%
Net Income, GAAP
- -
-61.47%
-444.81%
Sales/Revenue/Turnover
- -
14.1%
-5.78%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,789
2024
- -
- -
2,812
2025
- -
- -
2,649

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.13
2024
- -
- -
0.11
2025
- -
- -
-0.36

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
0.06
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yang Dong
Full Time Employees
3,494
Sector
Health services
Industry
Medical/Nursing services
Address
No. 301, North Jingsha Road Chengdu SI China 610000
IPO Date
Jun 25, 2019
Website
jxr-fertility.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Jinxin Fertility Group Limited, an investment holding entity, delivers advanced assisted reproductive services across mainland China and the United States. The company specializes in comprehensive treatment options, including artificial insemination, utilizing either partner or donor sperm, alongside advanced in vitro fertilization technologies such as conventional IVF and IVF with intracytoplasmic sperm injection. Beyond core fertility treatments, the group offers a suite of complementary services designed to support the entire patient journey, encompassing nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, Jinxin provides broader medical care including obstetrics, gynecology, and pediatrics, as well as managing ambulatory surgery centers and offering various ancillary medical services. The company is also involved in cutting-edge molecular genetics services, pre-implantation genetic screening, and cryopreservation techniques. Its operations extend to providing management solutions for fertility clinics and hospitals, alongside limited activities in property investment and real estate development. Established in 2018, Jinxin Fertility Group Limited maintains its corporate headquarters in Chengdu, China. The company has recently expanded its footprint with new facilities in Shenzhen and a satellite center in Beverly Hills, while strategically partnering with entities like Warburg Pincus to explore future acquisition opportunities. In 2025, the company introduced a new share scheme to enhance operational capabilities and align management incentives.